Taysha Gene Therapies Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 2, 36.33, 126.16, 479.49, 957.88 ], "ebit_estimate": [ -177.85, -177.55, -93.97, 94.65, 404.94 ], "ebitda_estimate": [ -176.9, -156.51, -1.56, null, null ], "net_income_estimate": [ -171.37, -167.86, -126.47, 94.95, 412.69 ], "per_share_eps_estimate": [ -0.48, -0.46, -0.34, 0.23, 1 ], "eps_nri_estimate": [ -0.48, -0.46, -0.35, 0.23, 1 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 0.22, null, null, null, null ], "pretax_income_estimate": [ -175.6, -170.9, -133.29, 101.8, 446.26 ], "operating_cash_flow_per_share_estimate": [ -0.45, -0.34, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -64.12, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null ], "operating_cash_flow_estimate": [ -164.99, -124.66, null, null, null ], "pettm_estimate": [ 0, 0, 0, 27.81, 6.34 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "187.87", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 187.87, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": 72.28, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 0.62, 0.62, 0.3, 0.6, 0.69, 5.42, 25.09 ], "ebit_estimate": [ -43.46, -44.57, -46.06, -48.19, -50.07, -46.15, -33.8 ], "ebitda_estimate": [ -45.8, -47.8, -51.26, -45.35, null, null, null ], "net_income_estimate": [ -42.7, -43.65, -45.44, -47.91, -49.33, -45.28, -26.31 ], "per_share_eps_estimate": [ -0.12, -0.12, -0.12, -0.21, -0.22, -0.09, 0 ], "eps_nri_estimate": [ -0.12, -0.12, -0.13, -0.13, -0.13, -0.12, -0.07 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 0.38, 0.3, 0.22, null, null, null, null ], "pretax_income_estimate": [ -42.43, -43.28, -44.43, -47.91, -49.33, -45.41, -26.74 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "187.87", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 187.87, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": 72.28, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }